Industry | 制造业 | ||||||||||||||||||||||||
Company Introduction | 四川金石亚洲医药股份有限公司于2015年在深交所创业板上市,通过数十年的行业积累和外延式发展,目前已成为覆盖研、产、销的医药健康和新材料及机械设备的综合性上市公司。金石亚药有着逾60年的发展历史。金石亚药医药板块,其前身海南亚洲制药股份有限公司发端于1962年。历经数十年积累,已成为经营范围全方位覆盖医药健康及食品保健等领域的研、产、销综合性企业。公司在浙江和海南两省建有总占地面积超300亩的生产基地。旗下拥有18家各类子公司。包括多家通过国家GMP认证的制药生产公司、多家通过国家GSP认证的医药销售公司、多家通过GSP认证并取得医保定点零售药店资格的药品销售连锁终端、取得国家食品药品监督管理局颁发的原料药碳酸钙生产注册批件的原料药制造公司、通过中国绿色建筑三星级标准和运营认证的杭州市级孵化器平台、零缺陷通过美国FDA、国家GMP核查的研发创新中心等实体;医药主营品种覆盖化学药制剂和原料药、中间体;中药制剂及药材;植物提取类及钙维矿类保健食品等多个领域。其中化学药制剂方面,公司在呼吸、消化、骨科、儿科等方向积极布局品种。公司是国内感冒药一线产品“快克?”和“小快克?”的品牌缔造者和拥有者,多年来,公司着力打造的产品线覆盖感冒清热、胃肠消化、清咽止咳、抗菌消炎和营养补充等领域。原料药、中间体方面,公司在盐酸金刚烷胺、原料药碳酸钙等领域拥有国家认证的资质和研发、生产与销售能力。其中原料药碳酸钙、食品添加剂碳酸钙、复配食品添加剂碳酸钙颗粒等三大主营品种广泛用于钙制剂产品和药用辅料生产制剂产品。植物提取保健食品端,公司在人参皂苷RH2提取领域拥有(多)项专利技术,生产和销售今幸系列优质的保健食品。综上,目前公司的主营品种,包含快克?、小快克?系列化学药、今幸系列人参提取类和钙维矿补益类保健食品,快克?本草系列中药饮片等三大系列共73个品种。其中核心品种快克?感冒药系列多年占据国内感冒类化学药最受欢迎和排名第一品种的位置,在感冒药赛道处于比较稳定的领先地位。金石亚药新材料及机械设备板块,业务起步于2004年,拥有三家新材料机械子公司。近20年来,始终秉持以科技促发展的理念,通过深度研发,已经成为新材料机械设备专项细分领域的绝对技术领先者和服务提供商。主营产品钢增强塑料复合管道技术的研发和应用、真空镀膜设备的研发和制造和垂直循环式立体停车库市场前景可观。公司崇尚和追求自由、健康、快乐的人生状态,希望以孜孜不倦的科技探索,创造大众生活的温馨与快乐。为此,公司始终秉持开放、开拓、开创的蓬勃精神,专注于满足客户需求,拥抱行业变革和抓住发展机会,不断开拓创新和进步。 | ||||||||||||||||||||||||
Main Business | 从事的主要业务分为医药健康和新材料与机械两个板块。 | ||||||||||||||||||||||||
Legal Representative | 马益平 | ||||||||||||||||||||||||
Top Executives |
|
||||||||||||||||||||||||
Top 5 Shareholder |
|
||||||||||||||||||||||||
Company Secretary | 林强 | ||||||||||||||||||||||||
Solicitors | 上海市锦天城律师事务所 | ||||||||||||||||||||||||
Auditors | 瑞华会计师事务所(特殊普通合伙) | ||||||||||||||||||||||||
Tel No | 028-87086807 | ||||||||||||||||||||||||
Fax No | 028-87086861 | ||||||||||||||||||||||||
Website | www.goldstone-group.com | ||||||||||||||||||||||||
goldstone@goldstone-group.com | |||||||||||||||||||||||||
Company Address |
|
||||||||||||||||||||||||
Listing Date | 24/04/2015 | ||||||||||||||||||||||||
Shares Capital |
|
||||||||||||||||||||||||
EPS(RMB)* | ¥ 0.310 | ||||||||||||||||||||||||
DPS(RMB)* | ¥ 0.110 | ||||||||||||||||||||||||
NBV Per Share(RMB)* | ¥ 5.975 | ||||||||||||||||||||||||
Market Capitalization(RMB) | 3.089B |
Only Chinese content is avaliable | |
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
* | Unadjusted Data |
Information provided by: etnet | ||
Terms and Conditions |
Risk Disclosure: |
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
Disclaimer: |
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |